Importance of Immunoglobulin Isotype in Human Antibody-Dependent, Cell-Mediated Cytotoxicity Directed by Murine Monoclonal Antibodies by Kipps, Thomas J. et al.
Haverford College 
Haverford Scholarship 
Faculty Publications Biology 
1985 
Importance of Immunoglobulin Isotype in Human Antibody-
Dependent, Cell-Mediated Cytotoxicity Directed by Murine 
Monoclonal Antibodies 
Thomas J. Kipps 
Peter Parnham 
Jenni Punt 
Haverford College 
Leonard A. Herzenberg 
Follow this and additional works at: https://scholarship.haverford.edu/biology_facpubs 
Repository Citation 
Kipps, T. K., P. Parham, J. Punt , L. A. Herzenberg. (1985). Importance of immunoglobulin isotype in hu 
man antibody - dependent, cell - mediated cytotoxicity directed by murine monoclonal antibodies. J. Exp. 
Med. 161:1 - 17. 
This Journal Article is brought to you for free and open access by the Biology at Haverford Scholarship. It has been 
accepted for inclusion in Faculty Publications by an authorized administrator of Haverford Scholarship. For more 
information, please contact nmedeiro@haverford.edu. 
IMPORTANCE OF IMMUNOGLOBUL IN  ISOTYPE IN 
HUMAN ANTIBODY-DEPENDENT,  CELL -MEDIATED 
CYTOTOXIC ITY  D IRECTED BY MURINE MONOCLONAL 
ANT IBODIES  
By THQMAS j. KIPPS,* PETER PARHAM,* JENNIFER PUNT,* AND 
LEONARD A. HERZENBERG* 
From the Departments of*Genetics and *Cell Biology, Stanford University School of Medicine, 
Stanford, California 94305 
There is considerable interest in using monoclonal antibodies (mAb) ~ as 
therapeutic adjuncts in treating human malignancy and in tissue transplantation 
(1,2). Several clinical trials involving tumor-specific murine mAb in the treatment 
of lymphomas (3, 4) have yielded promising results. However, the response to 
mAb in several other studies has been less satisfactory (5-7), indicating the 
presence of unknown variables that may strongly influence the outcome of such 
therapy. 
Critical to our appreciation of these variables is a better understanding of the 
interaction(s) between mouse Ig and the effector cells of the human immune 
system, mAb are suspected of mediating tumor cytolysis, not by activating 
complement (C), but by directing antibody-dependent, cell-mediated cytotoxicity 
(ADCC) (8). Indeed, tumor-specific Ig administered to mice depleted of C by 
cobra venom, retards the growth of transplanted tumor as readily as Ig admin- 
istered to animals with normal evels of C3 (9). Thus, the capacity of Fc receptor 
(FcR)-bearing killer (K) cells to recognize the heavy chain (H) of mouse Ig may 
be an important factor in the response to mAb therapy. 
Important in this regard is whether the H isotype of a murine mAb influences 
its capacity to direct ADCC by human effector cells. While some investigations 
(10, 11) indicate that all mouse mAb isotypes may direct ADCC by human 
effector cells, Koprowski and colleagues argue that only IgG2a is effective, at 
least in directing ADCC by human monocytes and macrophages (12). This latter 
contention is supported by the observation that cultured human monocytes 
interact only with murine IgG2a in ADCC (13). Moreover, Hellstrom et al. (14) 
and Imai et al. (15) have data suggesting that murine IgG2a antitumor antibodies 
are more efficient than IgG1 antibodies of like specificity in directing ADCC 
mediated by human K cells. Quantitative comparison of different mouse Ig 
This work was supported by grants GM17367, CA 04681, and AI01897. T. J. Kipps is a special 
fellow of the Leukemia Society of America. 
Abbreviations u ed in this paper: ADCC, antibody-dependent, cell-medlated cytotoxicity; DNP, 
dinitrophenyl; E/T, effector/target; FACS, fluorescence-activated cell sorter; FcR, Fc receptor; 
FITC, fluorescein isothiocyanate; H chain, heavy chain; K, killer; mAb, monoclonai ntibody; PBL, 
peripheral blood lymphocyte; RIA, radioimmunoassay. 
J. Exp. MED. © The Rockefeller University Press • 0022-1007/85/01/0001/17 $1.00 1 
Volume 161 January 1985 1-17 
2 Ig ISOTYPE IN HUMAN ADCC DIRECTED BY MURINE mAb 
isotypes for their ability to direct ADCC, however, has not been possible, because 
each of the mAb tested has been an independent hybridoma product with unique 
target antigen fine specificity and affinity. Precise analysis of  the role of isotype 
in mediating ADCC would require mAb of different isotypes with identical 
binding sites, to exclude the possibility that differences in the binding specificities 
or affinities are responsible for differences in ADCC. 
mAb fulfilling this requirement can be generated by selecting switch variant 
hybridoma cells which spontaneously express an H isotype different from that 
of the parent hybridomas, but retain expression of the same H variable region 
and light chains (16-18). Ig produced by members of such switch variant families 
have identical reactivities with antigens and differ only in isotype, thus permitting 
study of the dependence of  isotype in ADCC with no other antibody variables. 
Our  present studies on ADCC mediated by human peripheral blood lymphocytes 
(PBL) are directed by IgGl ,  IgG2b, or IgG2a produced by members of  two 
switch variant families specific for two HLA antigens expressed by cells of  a 
human B iymphoblastoid line, JY. 
Mater ials and Methods  
Cells. The human B iymphoblastoid cell line, JY, was used as the target cell in the 
ADCC assay. This cell expresses HLA antigens A2, B7, and DC-1 (19). ME1 and MA2.1 
are murine hybridoma cell lines. ME1, developed by Ellis et al. (20), secretes an IgGl 
with high affinity to HLA-B7, Bw22, Bw42, and B27. In addition to these strong reactions, 
this antibody cross-reacts weakly with HLA-B14 and a few other HLA-B locus products. 
MA2.1 secretes an IgG1 with high affinity for HLA-A2 and B17 (21). We selected the 
lgG2a and IgG2b isotype switch variants of ME1 and MA2.1 from their respective parent 
IgGl-producing hybridomas using the fluorescence-activated cell sorter (FACS), as de- 
scribed below. Cells were cultured in RPMI 1640 (Gibco Laboratories, Grand Island, NY) 
supplemented with 15% fetal calf serum (FCS) and 2 mM glutamine, and maintained at 
37°C in a humidified atmosphere with 7% CO2 in air. 
Monoclonal Antibodies. mAb specific for Leu-2a, Leu-7, Leu-lla, and Leu-15 were 
gifts from the Becton Dickinson Monoclonal Center, Inc. (Mountain View, CA). Mo2 was 
the gift of Coulter Immunology (Hialeah, FL). The IgG1 anti-DNP (dinitrophenyl) mAb 
and Texas Red-avidin were the gifts of Dr. R. Hardy (Genetics Dept., Stanford University, 
Palo Alto, CA). Antibodies 8.3, reactive with Igh-la, and 21-48.3, reactive with Igh-la, 
3a, are as described (22). 
Fluorochrome Conjugation of Antibodies. Isotype-specific goat anti-mouse antibodies and 
mAb 8.3 were conjugated to fluorescein isothiocyanate (FITC) as described by Goding 
(23). 
Multiparameter FACS Analysis. Immunofluorescence and light scatter analysis of PBL 
were performed on a dual laser FACS II as described (24). Fluorescein and phycoerythrin 
were excited at 488 nm by an argon laser. Texas Red was excited by an adjustable 
rhodamine dye laser at 600 nm. 
3 51 ADCC Assay. 80-t~l aliquots cohtaining 5 × 10" Cr-labeled JY target cells in RPMI 
1640 culture medium with 10% heat-inactivated FCS were added to individual wells of a 
96-well V-bottom microtiter plate. Purified antibody (from which aggregates wei'e re- 
moved by centrifugation i  a Beckman airfuge for 15 rain at 30 psi) was added to each 
well in 20 #1 isotonic phosphate-buffered saline (PBS), pH 7.4 to the final concentrations 
specified in the text. We incubated the cells with antibody for 20 min at room temperature, 
before adding 100 #1 of effector cells in culture medium to each well, at the specified 
effector/target (E/T) ratio. The plates were spun for 5 min at 200 g, and subsequently 
placed in a 37 °C incubator with humidified 7% CO~ in air. At times indicated in the text, 
the plates were again spun for 5 rain at 200 g and 100/~i of supernatant were harvested 
from each well. Samples were counted in a Beckman gamma scintillation counter. Wells 
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oflabeledJY with neither antibody or effector cells served as spontaneous release controls. 
Control wells of labeled JY with either antibody or effector cells were included in each 
experiment. Maximum counts were from wells of iabeledJY to which we added 100 #1 of 
5% Triton-X (Sigma Chemical Co., St. Louis, MO) instead of effector cells. The percent 
specific release was determined by the formula: [(sample - spontaneous release)/(maxi- 
mum counts - spontaneous release)] x 100. All samples were done in triplicate. Standard 
deviation of the mean for a given sample was calculated using an unbiased estimator for 
small samples (25). 
Isolation of Effector Cells for ADCC. Blood samples from healthy volunteers were 
gathered in heparinized syringes and diluted 1:1 with RPMI 1640 at room temperature. 
Leukocytes were isolated on FicolI-Hypaque (Pharmacia, Inc., Uppsala, Sweden) density 
gradients (0 = 1.08 g/ml). Mononuclear cells were harvested and washed three times 
before assay. Cell viability, as assessed by staining with acridine orange and ethidium 
bromide, was >95%. Where indicated, adherent cells were removed by incubating the 
isolated PBL on plastic culture dishes (Falcon Labware, Oxnard, CA) for 2 h at 37°C in 
culture medium supplemented with 10% heat-inactivated FCS. 
Radioiodination ofAntibodies. Purified anti-Igh la (8.3) or goat anti-mouse IgG mAb 
was radiolabeled with 12~I using the method of Hunter and Greenwood (26). 
Solid Phase Radioimmunoassay (RIA). mAb 21-48.3, anti-Igh la,3a (22), was used to 
coat polystyrene microtiter plates as described (27). After incubation with varying dilutions 
of culture supernates, and subsequent washing to remove unbound antibody, radiolabeled 
8.3 (anti-lgh la) or goat anti-IgG2b was used to detect IgG2a or IgG2b, respectively. 
Preparation oflg and Antibody Fragments. Antibodies were isolated from the ascites of 
hybridoma-bearing mice by ammonium sulfate salt precipitation and subsequent DEAE, 
then Sephadex G-200 size chromatography. The IgG2a and IgG2b MA2.1 were purified 
using Staph A-Sepharose in lieu of G-200 Sephadex chromatography as described (28). 
The Fab' and the F(ab')2 of the IgG1 ME1 were prepared as described (29). Goat 
antibodies pecific for either mouse IgG1 or IgG2 were prepared as reported previously 
(SO). 
8witch Variant Selection. IgG 1-producing parent hybridoma cell lines MA2.1 and ME 1 
bad been growing in tissue culture a minimum of 4 mo without subcloning. Since the 
proportion of switch variants within a given hybridoma population will generally increase 
with time (31), these lines were not subcloned before selection. Switch variant selection 
with fluorescein-conjugated antibodies specific for mouse IgG2 (goat anti-mouse IgG2) or 
IgG2a (mAb 8.3) was performed on a modified FACS II (B-D FACS Systems, Sunnyvale, 
CA) using a cloning apparatus that permits pauci-population sorting as described (18, 31). 
We took care that cell populations used for switch variant selection were >95% viable 
before staining. In addition, propidium iodide was used to stain dead cells so they could 
be excluded from FACS analysis and sorting (17). Pauci-population sorting permitted the 
cloning of switch variants after one round of selection. Culture supernatants of wells into 
which 1, 5, 25, or 100 brightly fluorescent ceils had been sorted were screened using a 
solid phase RIA for detection of the variant isotype. Cells that scored positive for the 
variant isotype were then stained again with FITC-goat anti-mouse IgG2 or FITC-8.3 
(anti-Igh 1 a). Single, stained cells were deposited into individual wells of microtiter plates. 
The proportion oflgG2b or IgG2a variants in either the ME1 or MA2.1 parent hybridoma 
populations was calculated by multiplying the initial sort frequency by the percentage of
cells identified as being switch variants in the sorted plates, using the Poisson distribution 
to calculate the number of variants per plate from data obtained in the RIA (18, 31). 
Cell-binding Assays. Radio-immune cell-binding assays to quantitate bound antibody 
were performed as described (32). Fluorescence-immune cell-binding assays to quantitate 
mouse antibody bound to JY were performed using FITC-conjugated goat anti-mouse Ig 
to stain washed cells that had been incubated for 20 rain with anti-HLA at specified 
concentrations. Propidium iodide at 1 #g/ml was used to stain dead cells so they could be 
excluded electronically from FACS analysis. Fluorescence data were collected using a 
modified FACS II equipped with logarithmic amplifiers. The mean fluorescence of 104 
cells from each sample was subsequently converted to linear units for comparison of 
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fluorescence intensity between samples. The percent of maximal binding was calculated 
by dividing this value by the maximum ean fluorescence value achieved with a saturating 
concentration f tested antibody. 
Results 
Isolation of Switch Variant Families. The IgGl-producing hybridomas ME1 
and MA2.1 were initially stained with isotype-specific, FITC-labeled, goat anti- 
mouse antibodies and found to be 90 and 97% positive for surface IgG1 
expression, respectively. Except for an extremely small fraction of cells in either 
population, no appreciable staining with goat anti-mouse IgG2 antibody was 
detected. The proportion of IgG2b switch variants within the ME1 hybridoma 
population, however, was high enough to permit direct cloning during the first 
round of variant selection (Table I). The IgG2a ME1, and IgG2b and IgG2a 
MA2.1 switch variants were cloned from sorted pauci-populations found to 
producing switch variant antibody by RIA. >95% of the cells from each cloned 
switch variant line stained positively for the newly acquired variant isotype using 
isotype-specific, FITC-conjugated antibody. Furthermore, <1 per 105 cells from 
such cloned switch variant lines stained for the parent surface IgG1. 
Quantitative Binding of Purified Antibodies Produced by the Switch Variant Fami- 
lies. Purified IgG1, IgG2a, and IgG2b of the ME1 switch variant family were 
compared by a radio-immune cell-binding assay to verify that no changes in 
either the specificity or avidity of the antibodies accompanied the isotype switch. 
As seen in Fig. 1 a, titration of all three isotypes against a fixed number of JY 
cells in an indirect trace-binding assay gave superimposable binding curves. The 
same assay, using a single saturating concentration of IgG (25 t~g/ml), demon- 
strated that the binding of each ME1 isotype, to a panel of 12 B lymphoblastoid 
cell lines of different HLA types, was the same (data not shown). Similarly, 
titration of the MA2.1 switch variant family of antibodies, in a fluorescence- 
immune cell-binding assay, demonstrated that all three have identical binding 
activities for JY (Fig. 1 b). These results confirm that the switch in the H constant 
region from IgG1 to IgG2a or IgG2b has no discernible ffect on the antigen- 
combining site of these anti-HLA antibodies. Thus, the Ig produced by these 
TABLE I 
Number of lsotype Switch Variants Detected inHybridoma 
Populations 
Average number of variants (X 10 -8) 
Hybridoma cell line 
IgG2b IgG2a 
ME1 1,600 64 
MA2.1 32 8 
Selection of switch variant families. Brightly fluorescent cells from 3 x 
108 hybridomas of either cell line stained with F1TC-goat anti-mouse 
IgG2 were sorted into individual wells of microtiter plates using the 
technique ofpauci-population sorting. Wells containing variants of either 
subclass were subsequently identified using a solid phase RIA. The average 
number of variants per sorted plate was calculated using the Poisson 
distribution. 
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FIGURE l. Titration of antibodies from switch variant families with JY: IgG1, IgG2a, and 
lgG2b antibodies of the ME1 switch variant family (left), or the MA2.1 family (right), were 
125 titered with a fixed number of JY. Specifically bound antibody was detected with I-labeled 
goat anti-mouse Ig (left), or with FITC-labeled goat anti-mouse Ig (right), for the radio- 
immune, or fluorescence-immune cell-binding assays, respectively. IgG1 (O), lgG2a (A), lgG2b 
(D).  
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FIGURE 2, ADCC of IgG2a ME1 antibody: 5~Cr-labeled JY was incubated with or without 
IgG2a ME1 at 10 ~g/ml, as described in Materials and Methods. PBL were added to an E/T 
ratio of 100:1. Bars indicate standard eviation (+SD) of percent specific lysis for triplicate 
samples. 
switch variant families were judged suitable for examining the effects of isotype 
on ADCC. 
Antibody-dependent Cell Cytotoxicity. Our preliminary studies demonstrated 
that the IgG2a ME1 can direct significant ADCC of JY by freshly isolated human 
PBL. Specific lysis of antibody-coated JY increased linearly with time, reaching 
a maximum of ~60% iysis in the 6 h period (Fig. 2). No significant lysis occurred 
in the absence of antibody, nor with nonspecific IgG2a antibody. Furthermore, 
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FIGURE 3. Comparison of ADCC activities of different antibody isotypes of ME1. Antibody 
at various concentrations was added to 51Cr-labeled JY. Percent specific lysis (+SD) is of JY 
after 4 h incubation with PBL at an E/T ratio of 50:1. lgG1 (Q), IgG2a (/k), IgG2b (I--1). 
IgG2a ME1 did not direct lysis of Daudi cells lacking HLA-B7 (data not shown). 
These results demonstrate hat lysis is due to ADCC. For comparing the different 
isotypes, an incubation time of 4 h was chosen. 
Comparison of ADCC Activity Directed by Different Isotypes. ADCC directed by 
IgG1, IgG2b, and IgG2a ME1 antibodies at a constant E/T ratio revealed that 
IgG2a provides the highest level of ADCC activity, effecting a maximal specific 
lysis of 25 + 2% at antibody concentrations >2 ~tg/ml (Fig. 3). The IgG2b 
subclass is significantly less effective, directing only 10 +_ 2% maximal lysis of JY. 
The fraction of maximal ysis directed by IgG2b and IgG2a at various concen- 
trations, however, are the same, consistent with these antibodies having identical 
binding affinities for theJY target cell. In contrast, no specific lysis of JY sensitized 
with IgG1 ME1 was detected, even at high antibody concentrations, and even 
when the assay time was extended to 19 h. Furthermore, cells killed with IgG2b 
ME1 increased with time, but remained significantly less than that of the IgG2a- 
coated JY at all time points tested (Fig. 4). 
We obtained similar results with the MA2.1 switch variant family (Fig. 5). 
IgG2a MA2.1 directed two- to threefold greater cell dependent lysis of JY at 
matched concentrations of IgG2b MA2.1, and IgG1 antibody gave no significant 
ADCC. 
Quantitation of Antibody Molecules Binding JY. Radiolabeled IgG2a ME1 was 
titered with JY under conditions identical to those used in the ADCC experi- 
ments. Reaching half-saturation at I /~g/ml, the binding curve closely paralleled 
ADCC activity. This demonstrates that a large proportion of the total HLA 
target molecules on JY must be bound by antibody for effective ADCC. At 
saturation, 5 X 10 6 Ig molecules bound. This approximates the number of 
surface HLA molecules perJY cell (33). 
Inhibition oflgG2a ADCC. ADCC directed by IgG2a ME1 is inhibited equally 
well by IgG1 ME1 or F(ab')2 ME1, on a molar basis (Fig. 6). This result confirms 
that the Fc domains of these antibodies are crucial for directing ADCC activity. 
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FIGURE 4. Kinetics of ADCC directed by the different isotypes of MEI. 5~Cr-labeledJY was 
incubated with antibody of each isotype at 10 gg/ml. ADCC (__SD) of PBL at an E/T ratio of 
50:1 was assayed at times indicated. IgG1 (O), IgG2a (&), IgG2b (0). 
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FIGURE 5. ADCC activities of different antibody isotypes of MA2.1. S~Cr-labeled JY was 
incubated with antibody of each isotype at various concentrations. Percent specific lysis (_SD) 
is of JY after 4 h incubation with PBL at an E/T ratio of 50:1. IgG1 (Q), IgG2a (Ix), IgG2b 
CO). 
The Fab' of ME1 is much less effective in blocking ADCC directed by IgG2a 
ME1, presumably because of the lost avidity of the univalent Fab' molecules. 
Comparable results for the inhibition of IgG2a-directed ADCC by IgG1 was 
noted in the MA2.1 system. 50% inhibition of ADCC directed by 4 t~g/ml of 
IgG2a MA2.1 (2.7 X 10 -8 M) was achieved with an equimolar concentration of
IgG1 MA2.1. IgG1 ME1, however, did not block ADCC directed by the non- 
cross-reacting I G2a MA2.1. Moreover, IgG1 MA2.1 did not inhibit IgG2a 
MEl-directed ADCC. These results confirm that inhibition with IgG1 is due to 
specific competition for binding to target HLA molecules, not in the interaction 
with effector (K) cells. 
Comparison of ADCC Activity in Different Individuals. Although there is consid- 
erable variability in the levels of ADCC activity observed with PBL isolated from 
different people, the relative capacities of the three Ig isotypes for directing 
ADCC were unchanged (Fig. 7). IgG2b ME1 directed levels of ADCC interme- 
diate to those of IgG2a, and the IgG 1 ME 1 was always ineffective. Furthermore, 
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FIGURE 6. Inhibition of IgG2a ME1 ADCC. The Fab', F(ab')2, or IgG1 of ME1 was added, 
at various concentrations, to separate wells containing ~Cr-labeled JY. lgG2a ME1 was 
subsequently added to 2.5 ttg/ml. After a 20 min incubation at room temperature, PBL were 
added to an E/T ratio of 50:1. ADCC was measured after 4 h incubation at 37°C. Samples 
without inhibitor had 30% (_+ 1%) specific lysis of JY with the lgG2a ME1. Percent inhibition 
of ADCC was determined by comparing the percent specific lysis of each sample with this 
value. IgG1 (e), F(ab')2 (&), Fab' (A). 
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FmURE 7. Comparison of ADCC activities of IgGI, IgG2a, and IgG2b ME I with PBL from 
different individuals. Antibodies of each isotype were incubated with SlCr-labeled JY at 5 ug/ 
ml. PBL from each individual were added at various concentrations to yield E/T ratios of 4, 
20, or 100:1. Samples were assayed after 4 h incubation at 37°C. IgGl (ZX), IgG2a (O), IgG2b 
(O).  
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the maximum levels of ADCC with IgG2b at different E/T ratios tended to 
parallel the levels found with IgG2a at these E/T ratios. 
Characterization fEffector Cells. To assess the ADCC activity of PBL depleted 
of monocytes, we compared the activity of unfractionated PBL with PBL not 
adhering to plastic after 2 h incubation at 37°C. These nonadherent cells 
represented -85% of the freshly isolated mononuclear cells, were >98% free of 
monocytes (assessed by morphology after staining with Wright-Giemsa), and 
possessed all the ADCC activity of the total mononuclear PBL. This suggests 
that the PBL effector cells are nonadherent K cells (34). 
Several groups of investigators (35-37) have reported the development of 
mAb that are specific for surface molecules expressed by human K cells. Some 
of these antibodies have been found to specifically block K cell ADCC activity, 
presumably by binding the Fc receptors of such cells (35, 37). Prior incubation 
of mononuclear cells with one such anti-FcR antibody, anti-Leu-1 la, abrogated 
the ADCC activity of the PBL for IgG2a-coatedJY (Table II). Other antibodies, 
anti-Leu-2a, anti-Leu-7, and anti-Leu-15, which reportedly bind to human K 
cells but do not block the FcR (38-40), gave no inhibition of ADCC directed by 
IgG2a anti-HLA of either specificity. Furthermore, murine IgG1 anti-DNP mAb 
of the same isotype as the anti-Leu-1 la gave no inhibition of ADCC. Comparable 
results were obtained with IgG2b ME1-and  IgG2a MA2.1-directed ADCC 
(data not shown). 
Multiparameter fluorescence and light scatter analysis of PBL confirms that 
ceils expressing Leu-1 la have the forward and obtuse angle light scatter char- 
acteristics of large lymphocytes, which can readily be distinguished from cells 
expressing Mo2, a monocyte differentiation antigen (41). The light scatter of 
whole, ungated PBL is shown in Fig. 8a. A box enclosing 95% of the Leu-1 la ÷ 
cells (Fig. 8b) excludes 96% of Mo2-expressing monocytes (Fig. 8c). All cells 
TABLE II 
Inhibition of ADCC by Anti-FcR Antibody 
IgG2a ME1 Antibody added to effector ADCC (+_.SD) added to JY cells 
+ - -  29 (2) 
+ Anti-Leu-2a 25 (3) 
+ Anti-Leu-7 28 (2) 
+ Anti-Leu-1 la 2 (3) 
+ Anti-Leu-I  5 27 (2) 
+ Ant i -DNP 25 (3) 
- - -  o (1 )  
- Anti-Leu-2a 2 (2) 
- Anti-Leu-7 2 (1) 
- Anti-Leu-I  la 0 (1) 
- Anti-Leu-15 1 (1) 
- Ant i -DNP 0 (1) 
Inhibition of  ADCC by anti-FcR: 5JCr-labeled JY were incubated with or 
without IgG2a MEI at 4 #g/ml.  PBL were incubated with 1.5 #g/10 s cells 
of  mAb at 25 #g/ml for 20 rain at room temperature.  PBL were washed 
free of  unbound antibody and added to JY at an E /T  ratio of  50:1. ADCC 
was assayed after 4 h incubation at 37°C. 
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FIGURE 9. Cell surface antigen distribution of Leu-I la + cells. PBL were stained with phy- 
coerythrin-conjugated anti-Leu-15, FITC-labeled anti-Leu-1 la, and biotin-conjugated anti- 
Leu-2a (a and b) or biotin-conjugated anti-Leu-7 (c and d). After washing away unbound 
antibody, cells were stained with Texas Red-avidin as a second step. a and c demonstrate he 
staining of ungated lymphocytes with anti-Leu-15/anti-Leu-2a, and anti-Leu-15/anti-Leu-7, 
respectively, b and d depict he distribution of cell surface antigens on the 10% of cells staining 
positively for Leu-I la. Numbers on the ordinate and abscissa indicate relative fluorescence 
intensity. 
expressing Leu-1 la also express Leu-15 (Fig. 9,b and d), the receptor for C3bi 
(42). Approximately half of the Leu-1 la + cells stained dully with anti-Leu-2a 
(Fig. 9b), and less than half stained positively with anti-Leu-7 (Fig. 9d). 
To enrich for cells expressing Leu-1 la without staining with anti-Leu-I la 
antibody, PBL were stained with phycoerythrin-conjugated anti-Leu-15 and 
sorted into separate subpopulations based on light scatter and fluorescence. PBL 
depleted of monocytes by FACS sorting (based on light scatter) possessed ADCC 
activity comparable to, or greater than, PBL from unsorted populations (Table 
III). Lymphocytes expressing Leu-I 5, however, had even greater ADCC activity. 
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TABLE II I  
lgG2a ADCC Activities of Selected Lymphoid Populations 
Population Percent 
of total 
ADCC at various E/T ratios 
(__SD) 
4:1 20:1 100:1 
Unseparated PBL 100 6 (1) 24 (2) 52 (3) 
Monocyte-depleted 95 6 (1) 31 (2) 57 (1) 
Leu-15 + lymphocytes 29 15 (1) 52 (1) NT 
Leu-15 - lymphocytes 67 1 (1) 5 (3) NT 
IgG2a ADCC activities of selected lymphoid populations. Unstained PBL 
were sorted on the basis of light scatter to exclude monocytes. In addition, 
PBL were stained with phycoerythrin-anti-Leu-15 andsorted on the basis 
of fluorescence and light scatter. The three sorted populations were 
compared with the untreated PBL at various E/T ratios for ADCC activity 
directed by 4 ug/ml IgG2a ME1 against SICr-labeled JY. ADCC was 
measured after 4 h incubation at 37°C degrees. Lymphocytes were de- 
pleted of monocytes by light scatter. NT, not tested. 
In contrast, cells not expressing Leu-15 had no ADCC activity, although these 
cells represented ~70% of the unfractionated PBL. 
Discussion 
In this study, we directly compared the activity of the IgG1, IgG2a, and !gG2b 
isotypes of otherwise identical mouse anti-HLA antibodies directing human PBL 
in ADCC against a B lymphoblastoid target. For antibodies of both the ME1 and 
MA2.1 switch variant families, we demonstrate that the IgG2a isotype is most 
effective, IgG2b less effective, and IgG1 completely ineffective in directing 
ADCC by human K cells. 
The inactivity of IgG1 antibody in directing ADCC conflicts with some 
published reports of ADCC directed by this isotype (10, 43, 44). In contrast o 
the IgG1 antibodies of both ME1 and MA2.1, the IgG1 antibody that directed 
high levels of ADCC in one of these studies also directs efficient C-mediated 
cytolysis of antigen-bearing cells (10). Generally, of the murine IgG isotypes, 
only IgG2a and IgG2b are effective in C=mediated lysis (30, 45). In particular, 
this is true for antibodies o f  both MEI and MA2.1 switch variant families 
(unpublished observations). Some mouse IgG1 antibodies, however, can effec- 
tively fix C (46-48). This may be due to unusual (variable-constant) V-C region 
interactions or posttranslational modification of the C region. This may also 
explain, in part, why some IgG1 can direct ADCC by human K cells. Further- 
more, differences in the ADCC assay, such as higher E/T ratios, longer incuba- 
tion times, or different arget cells, may permit IgG1 antibodies to direct ADCC. 
Our studies uggest, however, that an IgG2a antibody generally would be more 
effective than an IgG1 antibody of  the same specificity. This is in agreement 
with Hellstrom et  al. (14) and Imai et al. (15), who noted greater effectiveness 
of murine IgG2a over IgG1 of like specificity in directing human PBL in ADCC 
against human melanoma cell lines. 
Our studies differ in several important respects from those of Steplewski et al. 
(13), who concluded that IgG2a is the only effective murine antibody isotype for 
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directing lysis of a human tumor cell line by human effector cells. These 
investigators studied the effector activity of adherent PBL activated by weeks of 
in vitro culture. In contrast, the ADCC activities tudied here are mediated by 
freshly isolated nonadherent Leu-15 + cells that are inhibited by anti-Leu-1 la, an 
antibody that does not react with monocyte FcR. 
Some of these differences may explain our finding of intermediate l vels of 
ADCC activity directed by antibody of the IgG2b isotype, in contrast o .the 
apparent inactivity of this subclass reported by Steplewski et al. (13). Aside from 
the possibility that the IgG2b antibody studied by these investigators may not 
have the fine binding specificity and/or affinity necessary for directing ADCC, 
the differences noted in the activity of IgG2b could be related to differences in 
the FcR of the two effector populations tudied. Several mAb, including Leu- 
1 la (37), are specific for the human K cell FcR, a pronase-sensitive, trypsin- 
resistant membrane protein of 52,000-58,000 mol wt (35, 47). These same mAb 
do not bind the human monocyte FcR, which has an apparent molecular weight 
of 72,000 (48). However, it has been reported recently that 3G8, an mAb that 
reacts with an FcR protein that co-modulates with Leu-1 la on human K cells 
(37), also specifically binds a protein expressed by 60% of the macrophages 
isolated from resected lung tissue (49). This finding, plus the observation that 
the antigen detected by 3G8 is not expressed on monocytes unless they are 
cultured in vitro for several days, supports the idea that the FcR present on 
peripheral blood K cells is similar to or the same as that expressed on activated 
macrophages. 
Our data also indicate that human K cells interact preferentially with antibody 
bound to ceils. If free antibody readily bound to the effectors' FcR, saturation 
of available FcR would occur at high free antibody concentrations. This would 
give a prozone effect with diminished cytolysis of JY by PBL at higher than 
saturating concentrations of added antibody. That neither IgG2a nor IgG2b 
anti-HLA Ig inhibit ADCC at high antibody concentrations, as seen in Figs. 4 
and 6, shows that free antibody cannot compete successfully with cell-bound 
antibody for FcR of human K cells. This is further supported by our inability to 
activate effector cells for ADCC of JY by precoating the PBL with the IgG2a 
ME1 or MA2.1. After washing away unbound antibody, these preincubated PBL 
had no cytolytic activity for uncoated JY, although they still had the expected 
activity against IgG2a-coated JY (data not shown). 
In sharp contrast, others (14, 50-52) have demonstrated that there is a prozone 
effect when titrating human ADCC activity with increasing concentrations of
added specific antibody. Several of these studies used antisera, not purified mAb, 
to direct ADCC (50-52). Titrations performed with such heterogenous mixtures 
would reflect the ADCC activities directed by unknown fractions of antibodies 
with different isotypes. If, for example, a high affinity antibody of an isotype 
capable of directing ADCC, is present along with low affinity antibodies of 
isotypes less active in directing ADCC, ADCC would be greater at low concen- 
trations of added antisera, where the binding of high affinity antibodies would 
be favored. Also, without ultracentrifugation f Ig samples before testing for 
ADCC (as we did in this study), preparations of mAb or antisera may contain Ig 
aggregates that would directly bind the FcR of effector cells. Such aggregates 
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would compete with antibody bound to target cells and inhibit ADCC at higher 
serum concentrations. 
The vast differences in the capabilities of different isotypes of the ME1 and 
MA2.1 antibodies to direct ADCC in vitro makes us consider whether the in 
vivo biologic activity of a particular mAb may be dependent upon its isotype. 
Studies comparing the activities of different isotypes derived from switch variant 
families in the immunotherapy of various human diseases need to be performed 
to test this hypothesis. 
Summary 
Using the fluorescence activated cell sorter to select rare IgG2a- and IgG2b- 
producing variants, we developed switch variant families of hybridomas from 
IgG 1-producing hybridomas, ME 1 and MA2.1. The IgG2a and IgG2b antibodies 
produced by such switch variants have the same binding activities for HLA as 
the IgG 1 antibodies produced by the parent hybridomas. Using these antibodies, 
we directly compared the IgG 1, IgG2a, and IgG2b murine Ig isotypes for their 
capacities to direct human peripheral blood lymphocytes (PBL) in antibody- 
dependent cell-mediated cytotoxicity (ADCC) against a B lymphoblastoid cell 
line. We demonstrate that, for antibodies of identical binding affinity and 
specificity, the murine IgG2a isotype is the most effective in directing ADCC by 
human effector cells. The murine IgG2b directs intermediate l vels of ADCC 
activity while IgG1 is inactive. We identified the effector cells in human PBL 
that mediate IgG2a or IgG2b ADCC as nonadherent killer (K) cells. These cells 
express the C3bi receptor and have cytolytic activity which is specifically blocked 
by a monoclonal ntibody (anti-Leu-11 a)that binds the Fc receptor (FcR) of such 
cells. Finally, FcR-bearing K cells bind to target cell-bound, rather than free, 
IgG2a or IgG2b molecules. 
We wish to thank Dr. Lewis Lanier for many helpful discussions. In addition, we thank 
Ms. Linda Lloyd for her help in preparing this manuscript for publication. 
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